INNOVADERM-RESEARCH
1.5.2024 13:01:27 CEST | Business Wire | Press release
Innovaderm, the leading medical dermatology and aesthetics Contract Research Organization (CRO), today announced that it has been selected by Clinical Leaders CRO Leadership Awards for the fourth consecutive year, excelling across core categories of Expertise, Capabilities, Quality, and Reliability.
Clinical Leaders CRO Leadership Awards, which include a collaboration with ISR Reports, provide readers with accurate and reliable customer feedback to assist them in choosing a reputable CRO partner. This year, more than 40 CROs were assessed on approximately 20 performance metrics on work completed in the past 18 months.
Innovaderm won top performer for “small pharma” in the Capabilities, Quality, and Reliability categories, and named champion in the Expertise (Overall, Small Pharma) category.
“We are proud to be recognized by the CRO Leadership Awards for the 4th year running,” said Cedric Burg, COO at Innovaderm. “This honor is a testament to our unwavering commitment to excellence in dermatology and aesthetics clinical research. Our team’s dedication to providing top-tier service and delivering quality results has been instrumental in achieving this recognition. We remain committed to our mission of improving patients’ lives and will continue to strive for excellence in all that we do.”
With nearly 25 years of success and deep expertise in medical dermatology and aesthetics, Innovaderm stands as a leader in dermatology clinical research. The CRO’s comprehensive approach includes full-service capabilities and stand-alone biometrics and clinical regulatory services across all phases of clinical trials. Innovaderm excels in managing both late phase and early phase & translational studies. The operational teams, established in Europe and North America, are dedicated to improving patient lives. This commitment to excellence underscores every aspect of Innovaderm’s mission.
Innovaderm Research Inc.
Innovaderm Research Inc. is the leading full-service dermatology CRO. Founded in 2000, Innovaderm’s deep expertise and experience enable the ability to operationalize all aspects of clinical research, and deliver excellence across early to late phase studies. Innovaderm’s mission is to drive innovative research initiatives towards the goal of improving patients’ lives. To learn about Innovaderm’s services, visit our website.
Innovaderm Research Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501792630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye’s Most Significant Wind Energy Projects2.2.2026 09:00:00 CET | Press release
Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 08:00:00 CET | Press release
Delivery of the Black Hornet UAV systems to Swiss Armed Forces will include drones with software and integration kit specially designed to work with Piranha 8x8 vehicle digital infrastructureWork shows promise and market potential for UAS armored vehicle integrations to enhance tactical operations Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom